MR. CHARLES HAY (Orcid ID: 0000-0003-3496-7044)
DR. EDWARD RODDY (Orcid ID: 0000-0002-8954-7082)

Article type: Reply to Letter to the Editor

Reply to Dr. Lai regarding Allopurinol Hypersensitivity Syndrome in patients of Asian ancestry

Charles A Hay MA1, James A Prior PhD1, 2, Christian D Mallen PhD2, John Belcher PhD3, Ed Roddy PhD1

Affiliations:

1 School of Medicine, Keele University, UK
2 Department of International Public Health, Liverpool School of Tropical Diseases, UK
3 School of Computing and Mathematics, Keele University, UK

Mr Charles A Hay
School of Medicine,
Keele University,
Staffordshire,
ST5 5BG,
United Kingdom
Email – c.hay@keele.ac.uk
Tel - 01782 734986

Word Count: 168

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/acr.24777

This article is protected by copyright. All rights reserved
Sir,

We thank Dr Lai for their interest in our study (1). While we did not show a statistically significant link between the use of allopurinol and mortality in people with gout, we agree that Allopurinol Hypersensitivity Syndrome (AHS) is the most serious side-effect of allopurinol, particularly in populations with South East Asian ancestry, leading to the recommendation to screen people of South East Asian descent for the HLA-B*5801 allele prior to starting treatment with allopurinol (2,3).

While AHS can be fatal, its incidence is low. One study reported an incidence of AHS in a large South East Asian sample of 4.68 per 1000 new users of allopurinol and related mortality of 0.39 per 1000 new users (4).

Investigation of the mortality risk from AHS was outside the purview of our study, which aimed to compare all-cause and cardiovascular mortality between allopurinol users and non-users, but we agree AHS is an important consideration for all clinicians managing gout, of which all patients starting allopurinol should be made aware.

Funding
CAH is funded by a NIHR School for Primary Care Research PhD Studentship. CDM is funded by the NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands, the NIHR SPCR, and an NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR (UK). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Conflicts of Interest
The authors declare they have no conflicts of interest

References
